Skip to content
中文产业新闻评分53Chinese source

阿斯利康以20亿美元入股Summit Therapeutics获12%股权，押注双抗药物依沃西

20亿美元！阿斯利康重金入股Summit，押注中国双抗药物挑战K药

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.